The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

Roche has received FDA approval for its antibody treatment Gazyva to be used in combination with standard therapy for adults with active lupus ...

The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from ...

Lupus treatment is different for different people. That’s because no two cases of lupus are the same — each person experiences lupus differently. That’s why it’s so important to work closely with your ...

With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October ...

Please provide your email address to receive an email when new articles are posted on . None of the eligible trials received a “good” diversity rating for race and ethnicity. Access-related barriers ...